Clinical Significance of Community-acquired Respiratory Virus Infection &

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the clinical significance of community-acquired respiratory virus (CARV) infection in patients with lung transplantation;Explore the lung microbiome dynamics within one year after lung transplantation;Find the relationship between lung microbiome and chronic lung allograft dysfunction(CLAD).

Clinical Trial Description

Title:Clinical Significance of Community-acquired Respiratory Virus Infection and Longitudinal Analysis of the Lung Microbiome in Lung Transplantation.

Background:Infection affects the short-term prognosis of patients with lung transplantation and chronic lung allograft dysfunction(CLAD) limits their long-term survival.It is important to provide more theoretical support for early diagnosis and treatment of acute respiratory tract infection and CLAD in patients with lung transplantation.

Study Objectives:Evaluate the clinical significance of community-acquired respiratory virus (CARV) infection in patients with lung transplantation;Explore the lung microbiome dynamics within one year after lung transplantation;Find the relationship between lung microbiome and CLAD.

Study Design:A prospective and longitudinal study,following up the patients for 3 years.

Sample Size:100 cases. Study methods:CARV detection for respiratory specimens are performed during acute infection and routine re-testing in patients after lung transplantation,following up the patients who have positive findings to analyze the progression rates to lower respiratory tract infection,mortality rate within 90 days and risk factors associated with progression and death.For HRV/CoVs/HBoV detecting positive patients, consecutively collect respiratory specimens to quantitate viral load and combine virus serology to further confirm their pathogenicity on host.Complete a longitudinal 16S ribosomal RNA and metagenomics survey of the lung microbiome on respiratory samples collected from routine testing or re-testing（pre-operation,24 hours after the operation，day 3, day 7, week 2, week 3, month 1, month 3, month 6, month 9, month 12 , month 18, month 24, month 30, month 36) to explore the lung microbiome dynamics within one year after lung transplantation and find the relationship between lung microbiome and CLAD after 3 years follow-up.Besides,collect the peripheral blood of some patients for transcriptome and/or whole genome sequencing to screen for the host susceptibility genes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03545919
Study type	Observational
Source	Capital Medical University
Contact	Si si Du, Ph.D
Phone	86 13512916908
Email	dusisi511@126.com
Status	Recruiting
Phase
Start date	August 5, 2018
Completion date	June 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT06309628` - Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy
Withdrawn	`NCT02893176` - Macitentan in the Treatment of Organ Rejection After Lung Transplantation	Phase 4
Completed	`NCT02441413` - Transplant Optimization Using Functional Imaging (TROFI)	N/A
Recruiting	`NCT05375149` - Exhaled Breath Particles in Lung Transplantation
Active, not recruiting	`NCT03967340` - PREdiction of Chronic LUng Allograft Dysfunction
Active, not recruiting	`NCT05260372` - Next Generation Sequencing to Detect Acute Rejection in Lung Transplant Patients.
Recruiting	`NCT06082037` - A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction	Phase 3
Recruiting	`NCT04714801` - Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation	Phase 1/Phase 2
Active, not recruiting	`NCT05170425` - LAMBDA 002 (Lung Registry) Study
Completed	`NCT02474927` - Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation	Phase 2
Recruiting	`NCT05006742` - Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients	N/A
Recruiting	`NCT02812290` - Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation
Not yet recruiting	`NCT03500575` - Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients	N/A
Withdrawn	`NCT03805178` - Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization	Phase 2
Completed	`NCT03359863` - Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction	Phase 2
Active, not recruiting	`NCT03656926` - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)	Phase 3
Completed	`NCT01985412` - Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection
Completed	`NCT04234919` - Longitudinal Study of Cell Free DNA in Lung Transplant
Recruiting	`NCT04837339` - Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation	N/A
Recruiting	`NCT03090581` - Transbronchial Biopsies With Cryoprobe in Patients With Lung Transplantation.	N/A